Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915

Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915

Purpose CheckMate 915 (NCT03068455) compared adjuvant nivolumab monotherapy versus combination nivolumab+ipilimumab in patients with resected stage III/IV melanoma. This exploratory analysis was performed to identify biomarkers that correlate with benefit from adjuvant immunotherapy.Patients and met...

Full description

Saved in:
Bibliographic Details
Main Authors: James Larkin, Jeffrey Weber, Georgina V Long, Jonathan Baden, Hao Tang, Corey Ritchings, Michele Del Vecchio, Keyur Desai, Daniel Tenney, Han Chang, Gina Fusaro, David Balli, Sonia Dolfi, Sheen Wang, Shu-Pang Huang
Format: Article
Language:English
Published: BMJ Publishing Group 2025-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/7/e012034.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/7/e012034.full

Similar Items